Follicular lymphoma is the second most common type of non-Hodgkin lymphoma in adults. The environmental and genetic factors that influence the susceptibility of this cancer are not completely understood.

Multiple Myeloma (MM) is a B-cell malignancy morphologically characterized by a monoclonal proliferation of plasma cells in the bone marrow. The causes of MM are poorly understood and its prognosis is poor.

Glioma is the most common type of brain cancer. It is extremely aggressive and yet understudied. We are conducting a family case-control study of glioma in Australia.

Cancer of unknown primary (CUP) is a diagnosis used to describe patients with metastatic cancer with no identifiable primary site of origin at the time of presentation. CUP is the fourth most common cause of cancer death in NSW, but little is known about its risk factors or management.

We are collaborating on a number of international pooled analyses being conducted under the auspices of the International Lymphoma Epidemiology Consortium (InterLymph).

We are estimating and comparing the population-level relevance of risk factors for cancer in Australia by applying our recently published PAF measure and program to data from established large-scale Australian cohort studies linked to national cancer and death registries (relative risk estimates)

Uganda is one of three target regions where the University of New South Wales aims to improve the lives of one million people by 2025.

The aims of this Fellowship are to utilise and further extend recently developed methods for estimating different aspects of disease burden in order to:

This is a matched cohort study examining survival and prognostic factors after melanoma diagnosis in kidney transplant recipients. The study is a collaboration with ANZDATA, the University of Sydney, and St Vincent's Hospital Melbourne.

This project utilises health record linkage to quantify the risk of cancer in opioid dependent people registered for pharmacotherapy in NSW. We will examine the relationship between cancer risk and infection with the blood-borne viruses hepatitis B, hepatitis C and HIV.